Jansen Loeb

ProEncía Biotechnology, a Minnesota-based innovative periodontal care company, is committed to fighting periodontal disease through unique, ground-breaking treatments. The company has developed multiple products, including an OTC prophylactic and an RX therapeutic, to regenerate and restore oral tissue health.

Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.

CAGE Bio Inc. is a privately-held clinical-stage company exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology

ProEncía Biotechnology, a Minnesota-based innovative periodontal care company, is committed to fighting periodontal disease through unique, ground-breaking treatments. The company has developed multiple products, including an OTC prophylactic and an RX therapeutic, to regenerate and restore oral tissue health.

Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.

CAGE Bio Inc. is a privately-held clinical-stage company exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology